High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
about
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHepatic late adverse effects after antineoplastic treatment for childhood cancerLong-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group studyIncorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 studyLong-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation.28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures.Local control in metastatic neuroblastoma in children over 1 year of agePilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyAdvances in Risk Classification and Treatment Strategies for Neuroblastoma.Clinical trials in paediatric haematology-oncology: are future successes threatened by the EU directive on the conduct of clinical trials?Autologous hematopoietic stem cell transplantation for pediatric solid tumors.Hematologic recovery after tandem high-dose chemotherapy and autologous stem cell transplantation in children with high-risk solid tumors.Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue SarcomasIdentification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach.Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaSIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsDNA vaccination: using the patient's immune system to overcome cancerDo pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.Neuroblastoma: a review of management and outcome.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.Not too little, not too much-just right! (Better ways to give high dose melphalan).Advances in emerging drugs for the treatment of neuroblastoma.Late-onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients.Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.Feasibility of sequential high-dose chemotherapy in advanced pediatric solid tumors.Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.Survival of high-risk pediatric neuroblastoma patients in a developing countryTreatment of high-risk neuroblastoma.Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group.Reply to N.-K.V. Cheung et alSurgical treatment of neuroblastoma: twenty-three years of experience at a single institution.A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
P2860
Q24186636-AA6864A7-85A8-498D-9D74-F85571D6128BQ24200296-AE00D9FC-EF1D-4F4E-B7CA-BF5B315A434BQ24235309-15EB59F5-76BA-4C27-8C24-EF89F3291735Q24235525-30EE529A-85FC-468A-A729-24DCEED753AEQ24658339-7B53ADC5-F7A0-477F-A786-7F9BF35FC3F2Q33691441-705235A6-27EE-48ED-A030-7E5F483D797BQ34667915-425A0EC1-17A3-4A22-8056-BB65B29EB30CQ34785880-B6B4B052-42CA-4681-B9B9-528E398D29E7Q35146875-7C568234-B8A2-4D74-B241-F4368CF99E2AQ35565630-C8492BC8-8E25-492D-94F5-2E443F286182Q36053801-AE052509-8977-4328-83A7-14761C90A057Q36155005-4AB0F7E6-2322-4E74-945F-384575A3B374Q36284506-1310680B-8BD4-44F1-A0DF-AB9C912B5A07Q36589477-61E65DDE-8489-4B30-B6CF-DC7A33DF57A4Q36615949-932D0302-3564-49F9-9136-1B09D97B559DQ36782374-8EAF3188-D2EC-48CC-AC6E-9B99E968138CQ36989758-95D37590-A53F-4287-BE17-6B7B04215D0AQ37067229-A2550E35-12E8-4C8A-89DC-DB2402DDC0D5Q37078231-D98DABAD-F180-42C7-8508-47EE76F3535AQ37461968-CFF4593E-9C60-44BC-AA9E-8192A0612A14Q37825422-A88C3125-5152-437A-83D1-840C1875868BQ37834445-FE5D1B38-9E1C-4A7E-804B-08C7DD481D9EQ37939996-35AF2D69-CC3E-4A6A-B1F2-82ED0DD35D68Q38005038-DCC5BF2B-CB36-4EDC-B66B-11ABDBDB2328Q38014527-1BFF4492-0AFB-45BF-ACE4-D9F24F8D9084Q38112088-463A5D60-D3AF-4563-B9DA-1B214E05DD75Q38161274-35D2E72D-09C9-47D3-9165-07D5A97A9B57Q38240941-ED316A9E-07F6-4AC0-B90F-1F23E0CEC1B0Q39158415-F7D842DF-B680-40B5-83A3-F11A7727B3E5Q39855262-552AC8A7-8AC7-4DAB-B23E-B34D41333A3BQ39865674-09847749-D90A-4060-BE3B-01783F8505A0Q40367223-7E21B26C-1A42-45DD-A6FD-C5A60588BFC1Q40367329-ECCC8AC1-4538-4003-86D9-8D5BABD41E42Q40518791-72700C58-C1A0-460D-B74C-749C3616C46BQ40731149-CC3589DF-20B7-4E8E-BDE9-C96F472F2841Q41761113-EDD64B7B-4D08-4392-A29B-C7B0E4E26485Q41946476-4AF6E7C4-3F49-41D6-B4FC-F86C1B8E322DQ42356970-4579B3F7-E36A-4A93-B1DF-9B0F5E9F7F53Q43478910-65BED019-A497-4514-AA5B-5DF03C5D5F50Q46842794-9D3F758F-3BD3-453C-BCDD-5FBCA8F0CA68
P2860
High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@ast
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@en
High dose melphalan in the tre ...... results of a randomised trial
@nl
type
label
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@ast
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@en
High dose melphalan in the tre ...... results of a randomised trial
@nl
prefLabel
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@ast
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@en
High dose melphalan in the tre ...... results of a randomised trial
@nl
P2093
P2860
P356
P1476
High dose melphalan in the tre ...... ean Neuroblastoma Study Group.
@en
P2093
David R Jones
Jan de Kraker
John Imeson
Jon Pritchard
Shirley M Germond
Simon J Cotterill
P2860
P304
P356
10.1002/PBC.20219
P577
2005-04-01T00:00:00Z